Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 2/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309684 | 1.00 | METTL3 (0.69) | METTL3ATMMAPT | |
| SCHEMBL23794042 | 0.87 | METTL3 (0.82) | METTL3ATM | |
| Acetophenone-Thiosemicarbazone SCHEMBL17666972 | 0.81 | METTL3 (1.00) | METTL3ATM | |
| Phenyl(Methyl)Thiosemicarbazone SCHEMBL757506 | 0.81 | METTL3 (1.00) | METTL3ATM | |
| Phenyl(Methyl)Thiosemicarbazone SCHEMBL14436799 | 0.81 | METTL3 (1.00) | METTL3ATM | |
| SCHEMBL5704442 | 0.81 | CTSL (0.56) | — | |
| SCHEMBL943308 | 0.80 | ATM (0.66) | METTL3ATM | |
| SCHEMBL943309 | 0.80 | ATM (0.66) | METTL3ATM | |
| SCHEMBL5525640 | 0.80 | METTL3 (0.72) | METTL3ATM | |
| SCHEMBL23515724 | 0.80 | METTL3 (0.72) | METTL3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| EP-2266623-A2 | Prodrugs containing novel bio-cleavable linkers | Piramal Life Sciences Limited (IN) | 2010-12-29 | — | — | EP | claimed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-3746081-B1 | PDE1 INHIBITORS FOR USE TO TREAT CARDIAC FAILURE AND CARDIOTOXICITY | INTRA CELLULAR THERAPIES INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UNIVERSITY OF ROCHESTER (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4581143-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | University of Rochester (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250018009-A1 | SERUM RESPONSE FACTOR REGENERATES SENESCENT CELLS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-01-16 | — | — | US | disclosed |
| US-20250019702-A1 | GATA4-TARGETED THERAPEUTICS FOR TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF ROCHESTER | 2025-01-16 | — | — | US | disclosed |
| EP-3542160-B1 | INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS | ICHOR LLC (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-4444881-A2 | GATA4-TARGETED THERAPEUTICS FOR TREATMENT OF CARDIAC HYPERTROPHY | University of Rochester (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2004112763-A2 | INHIBITION OF PROTEIN KINASE C-MU (PKD) AS A TREATMENT FOR CARDIAC HYPERTROPHY AND HEART FAILURE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-12-29 | — | — | WO | disclosed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | disclosed |
| EP-1434876-A1 | EXPRESSION PROFILING IN THE INTACT HUMAN HEART | The REGENTS OF THE UNIVERSITY OF COLORADO, A Body Corporate (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1356071-A2 | GENETICALLY ENGINEERED HERPES VIRUS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | The University of Chicago (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030096782-A1 | Expression profiling in the intact human heart | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2003-05-22 | — | — | US | disclosed |
| WO-2003023066-A1 | EXPRESSION PROFILING IN THE INTACT HUMAN HEART | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2003-03-20 | — | — | WO | disclosed |
| US-20020155432-A1 | Genetically engineered herpes virus for the treatment of cardiovascular disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-10-24 | — | — | US | disclosed |
| WO-2002045431-A2 | GENETICALLY ENGINEERED HERPES VIRUS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | THE UNIVERSITY OF CHICAGO (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UPF1, HNRNPF, RNMT | METTL3 91/4885ATM 4087/4885MAPT 2836/4885 |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | METTL3 1852/4885ATM 3774/4885MAPT 4304/4885 |
| US-20250019702-A1 | GATA4-TARGETED THERAPEUTICS FOR TREATMENT OF CARDIAC HYPERTROPHY | UPF1, TNNI3, TNNT2 | METTL3 447/4885ATM 3100/4885MAPT 4037/4885 |
| US-12605384-B2 | Uses | PDE2A, NPR1, PDE7A | METTL3 1148/4885ATM 3082/4885MAPT 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.